The enzyme nitric oxide synthase 2 (NOS2), often called inducible NOS, plays a central role in the inflammatory reactions that follow infection or tissue damage. NOS2 has been detected in virtually every cell type, and the NO it produces can perform both beneficial and detrimental actions. It is thus conceivable that regulatory mechanisms exist which control the timing and intensity of NO production by NOS2 in order to outweigh protective effects against detrimental ones. Since cyclic AMP inhibits numerous immunological reactions, studies have been carried out to determine whether cAMPdependent pathways could inhibit NOS2 expression as well. Pharmacological studies in cultured cells show that, depending on the cell type examined, increased cAMP can exert opposite effects on the endotoxin-or cytokine-induced expression of NOS2, being either stimulatory or inhibitory in macrophages, stimulatory in adipocytes, smooth muscle, skeletal muscle, and brain endothelial cells, and inhibitory in pancreatic, liver, and brain glial cells. Regulation of NOS2 gene transcription appears to be the primary mechanism of action of cAMP, and whether it is stimulatory or inhibitory hinges on the cell-specific regulation of transcription factors including CREB, NF-B, and C/EBP. Cyclic AMP must therefore be considered a modulator rather than a suppressor of NOS2 expression. This review summarizes evidence derived from in vitro studies, considers regulation of NOS2 by cAMP in vivo, and discusses possible therapeutic applications of cAMP treatment.-Galea, E., Feinstein, D. L. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J. 13, 2125-2137 (1999) 
beneficial and detrimental actions (for review, see refs 1, 2) . On the one hand, it can eliminate infiltrating microorganisms, reduce thrombosis, and improve blood supply to injured tissues. In contrast, excess production of NO can cause tissue damage and contribute to the development of a wide spectrum of diseases including septic shock, rheumatoid arthritis, cerebral ischemia, multiple sclerosis, and diabetes. It has been speculated that NO is such an efficient mechanism of protection that evolution has provided most cells with the capacity to express NOS2 despite the associated risk of damage (2) . Conceivably, regulatory mechanisms exist that control the timing and intensity of NO production by NOS2 in order to outweigh protective actions against detrimental ones.
For more than 10 years, 3Ј, 5Ј cyclic adenosine monophosphate (cyclic AMP, cAMP) has been considered a ubiquitous regulator of inflammatory and immunological reactions. Increases of intracellular cAMP block T lymphocyte activation (3), inhibit interleukin 1␤ (IL-1␤) and tumor necrosis factor ␣ (TNF-␣) release from macrophages (4, 5) , and, in endothelial cells, reduce expression of the adhesion molecules that mediate lymphocyte infiltration into damaged or infected tissues (6) . In brain glial cells, the elevation of cAMP by the endogenous neurotransmitter noradrenaline inhibits LPS-induced IL-1␤ expression (7) and interferon ␥ (IFN␥) -induced MHC class II expression (8) . This evidence has led to the notion that one physiological role of cAMP-dependent signaling is to suppress immune responses, thus minimizing damage to the host. However, regulation of NOS2 by cAMP does not conform to this general pattern, since cAMP can either stimulate or inhibit NOS2 expression, depending on the cell type. Here we will review the biochemical evidence for the dual regulation of NOS2 by cAMP, analyze possible molecular mechanisms involved, and discuss whether such regulation is of biological or therapeutical relevance.
SIGNAL TRANSDUCTION PATHWAYS MEDIATED BY cAMP
Cyclic AMP is a key and widespread mediator in the conversion of extracellular signals into intracellular events, and many of the components of its signaling pathway have been well characterized (for review, see refs 9, 10) . Binding of ligands to G-proteincoupled receptors induces release of stimulatory Gs proteins that activate the enzyme adenylate cyclase, which converts bound ATP to cAMP (11) . Increase of intracellular cAMP results in activation of protein kinase A (PKA), a tetramer of two catalytic (C) and two regulatory (R) subunits. On binding of cAMP, the R and C subunits rapidly dissociate, allowing C subunits to phosphorylate a wide spectrum of proteins including membrane receptors, cytoskeleton proteins, and a wide variety of phosphatases, kinases, and other enzymes (12) . Active PKA C subunits can also rapidly enter the nucleus (13) , where they phosphorylate and activate transcription factors (9) including CREB (cAMP response element binding protein), CREM (cAMP response element modulator), ATF-1 (activating transcription factor-1), and AP-2 (activator protein-2). Signaling by cAMP characteristically is transitory and followed by a refractory period (14) . Deactivating mechanisms are multiple and include desensitization of G-coupled receptors, degradation of cAMP by phosphodiesterases, inhibition of PKA by endogenous inhibitors, and activation of phosphatases that remove phosphorylations carried out by active PKA. Both stimulatory and inhibitory components of the cAMP-dependent cascade exist in several isoforms with different tissue distribution and regulatory properties (8, 11, 15) , providing a wide assortment of endogenous means to regulate cAMP signaling.
Experimentally, activation of cAMP-dependent signaling has been achieved by 1) activation of G-coupled receptors, 2) direct activation of adenylate cyclase with forskolin, 3) inhibition of cAMP degradation using selective phosphodiesterases inhibitors (i.e., rolipram or IBMX), 4) administration of membrane permeable cAMP analogs resistant to degradation by phosphodiesterases, including dibutyryl cAMP (dbcAMP) and 8-bromo-cAMP, and 5) inhibition of phosphatases with okadaic acid.
EFFECTS OF INTRACELLULAR cAMP ON NOS2 EXPRESSION IN VARIOUS CELL TYPES

Macrophages
Macrophages express NOS2 when exposed to cytokines or bacterial lipopolysaccharides (LPS), which stimulate transcription of the NOS2 gene (2). Characteristic inducers are IL-1␤, TNF-␣, and IFN␥, which often act synergistically. Sustained expression of NOS2 results in the production of vast amounts of NO (16) , which is able to kill bacteria, viruses, and tumor cells, but eventually is deleterious to the host cells, thus contributing to the pathogenesis of diseases like septic shock (17) and rheumatoid arthritis (18) . The pathophysiological relevance of NOS2 expression in macrophages has prompted numerous studies regarding its regulation by cAMP. As a result, a puzzling picture has emerged: as many studies report an inhibitory role as describe a stimulatory effect of cAMP.
Evidence that cAMP can up-regulate NOS2 expression was initially reported in rat Kupffer cells, the resident macrophage in liver (19, 20) , and then extended to rat peritoneal macrophages (21) (22) (23) , bone marrow-derived macrophages (24) , and macrophage cell lines (25-27; Table 1 ). The analogs dbcAMP and 8-bromo-cAMP, as well as forskolin, IBMX, rolipram, and cholera toxin, were used to elevate intracellular cAMP and cannabinol was used to decrease it. The overall conclusion drawn from these studies is that cAMP-dependent pathways can stimulate macrophage NOS2 expression up to fivefold. Additional evidence for a potentiating action of cAMP comes from studies of endogenously released prostaglandins. Thus, antibodies against prostaglandin E 2 (PGE 2 ) (19) or inhibition of the enzyme that synthesizes PGE 2 , cyclooxygenase (24, 25) , decreased the endotoxin or cytokine-induced expression of NOS2. Since PGE 2 increases cAMP levels in macrophages (64) , these results suggest that endotoxin or cytokines induce the release of PGE 2 , which potentiates NOS2 expression via elevation of intracellular cAMP.
It should be noted that most of the early studies of NOS2 expression relied on measurements of nitrite (a stable metabolite of NO) levels in the cell culture media from using Griess reagent (65) . Although not highly sensitive, the measurement of nitrites by this method provides an adequate measurement of NOS2 expression because the continuous production of NO by NOS2, combined with the stability of nitrites, results in sufficiently high nitrite concentrations. With the availability of NOS2 cDNA clones and selective anti-NOS2 antibodies, NOS2 expression has been more directly assessed by measurements of NOS2 mRNA levels and immunoblot analysis.
In direct contradiction to the above results, several other studies have described an inhibitory effect of PGE 2 , 8-bromo-cAMP, IBMX, and forskolin on NOS2 expression. For example, in the mouse macrophage J774 cell line, induction of NOS2 by LPS was decreased in a dose-dependent manner by coincubation with nanomolar amounts of PGE 2 or iloprost (a stable PGI 2 analog), which increase cAMP, but not by incubation with PGF2a, LTB4, or LTC4, prostanoids, which do not elevate intracellular cAMP (30) . Bulut et al. (31) also observed inhibition of NOS2 activity by PGE 2 in J774 cells, but required coincubation with IBMX, perhaps necessary to achieve higher and prolonged elevation of cAMP levels. In these studies (31), incubation with RpcAMP, a PKA inhibitor, reversed the effects of PGE 2 , indicating a role for cAMP and PKA. More recently it was shown that PGE 2 , PGI 2 , and forskolin could also decrease NOS2 expression in J774 cells in the absence of IBMX (32) , possibly due to having preincubated the cells with cAMP-elevating agents before the addition of LPS. Furthermore, inhibitory effects were not observed if the prostanoids were added after LPS addition, suggesting that cAMP interfered with early events in NOS2 expression, such as gene transcription, rather than with later events like mRNA turnover or protein translation.
Apart from the macrophage J774 cell line, inhibitory effects have also been described in macrophages from various tissue origins. In peritoneal macrophages, both LPS-induced NO production and the cytostatic action against tumor cells were increased by the cyclooxygenase inhibitor indomethacin and reduced by coincubation with PGE 2 (28) . It was concluded that this effect was mediated by cAMP, since treatment of cells with IBMX or 8-bromo-cAMP also reduced NO production. In rat liver macrophages, PGE 2 dose-dependently suppressed LPS-dependent nitrite accumulation (66) . Finally, in a more comprehensive study, forskolin treatment inhibited induction of NOS2 mRNA, protein, and nitrite accumulation in Kupffer cells (29) . Inhibition was also observed using dbcAMP, cholera toxin, and isoproterenol, although to a lesser extent than with forskolin; in all cases, the phosphodiesterase inhibitor IBMX further increased the inhibitory effects.
What is the basis for the conflicting effects of cAMP? Consideration of the following studies may help reconcile the discrepancies. In the first one (25) , low concentrations of PGE 2 increased NOS2 expression in J774 cells whereas higher doses caused inhibition. Second, Mullet et al. (26) reported that in the ANA-1 macrophage cell line, dbcAMP and the PKA activator Sp-cAMP lost the capacity to stimulate NOS2 or were clearly inhibitory when used at high (Ͼ100 M) concentrations (26) . Together, these results suggest that the extent of activation of cAMPdependent pathways dictates whether NOS2 expression is increased or decreased. Since the production of IL-1␤ and TNF-␣ (which can synergistically stimulate NOS2 expression) is blocked by increased intracellular cAMP (5, 67) , it is possible that the inhibitory effects of cAMP on NOS2 expression are the result of reduced release of proinflammatory cytokines. If so, a cAMP inducer like PGE 2 would be at the core of an autocrine regulatory loop: causing limited increases in cAMP at low levels, PGE 2 would enhance NOS2 expression directly; at higher levels, associated with larger cAMP increases, it would decrease NOS2 expression due to inhibition of cytokine release. This may explain why studies in which NOS2 expression is activated with LPS, which induces maximal stimulation and release of high amounts of PGE2, show inhibition of NOS2 by cAMP (29, 66) whereas studies using single cytokines, leading to less release of PGE2, report a stimulatory effect of cAMP (19, 22, 24, 39) . This interpretation implies that the PGE2/cAMP system may have a dual biological role in macrophages, which is to enhance initial inflammatory responses while inhibiting later events, lest excessive NO production cause tissue damage.
The complexity of the findings in vivo mirrors that in vitro. Stimulation of the sympathetic system, believed to exert control over leukocyte activation (reviewed in ref 68) , resulted in decreased NO production in alveolar macrophages (69) . In contrast, intrathecal administration of dbcAMP in rats induced NOS2 mRNA and protein in alveolar macrophages (33) . One intriguing difference between the latter study and in vitro analyses is that in cultured macrophages, dbcAMP on its own exerted no significant effect, whereas dbcAMP alone in vivo elicited NOS2 expression comparable to that induced by LPS. This suggests that LPS and cAMP trigger independent signal transduction mechanisms leading to NOS2 expression and that cAMPdependent signaling may be attenuated in vitro and, thus, appear mostly as modulatory of the endotoxinor cytokine-elicited response.
Smooth muscle and smooth muscle-derived cells
Aorta smooth muscle
IFN␥, IL-1␤, and TNF-␣ induce the appearance of NOS2 mRNA and protein in cultured smooth muscle cells from rat aorta. This is believed to reproduce events associated with sepsis, atherosclerosis, and arterial injury after balloon angioplasty, where NOS2 may be induced in arterial walls by cytokines released by locally infiltrated leukocytes (70) .
In contrast to results observed in macrophages, all reports to date indicate that cAMP potentiates NOS2 expression in smooth muscle cells. Koide et al. (35) demonstrated not only that cultured rat aortic smooth muscle cells could respond (albeit to a small extent) to both forskolin and dbcAMP, but, more important, that these reagents increased (by up to fourfold) NOS2 expression induced by IFN␥. These findings have been reproduced using IL-1␤ or TNF-␣ to induce NOS2 expression, and phosphodiesterase inhibitors or stimulators of PKA to elevate cAMP (40) . The fact that comparable potentiation by cAMP was observed with either IFN␥, IL-1␤, or TNF-␣ indicates that, in smooth muscle cells, cAMP is most likely up-regulating a step common to all cytokines.
Agonists of G-coupled receptors, including the ␤-adrenoreceptor agonist isoproterenol (36) , CGRP (71), prostanoids (35) , and adenosine (42, 72) , also potentiated the induction of NOS2 by cytokines, although the effect was moderate compared to the one elicited by forskolin or lipophilic cAMP analogs. This is not surprising, as the accumulation of intracellular cAMP after stimulation of G-protein-coupled receptors is lower than the accumulation achieved with direct stimulation of adenylate cyclase or the use of nonmetabolizable cAMP analogs (35) . Hence, the effect of cAMP on expression of NOS2 in smooth muscle is, as in macrophages, dependent on the intensity of stimulus and can be incrementally regulated. However, unlike macrophages (25, 26) , the highest concentrations of cAMP analogs tested do not result in inhibition of NOS2 expression in smooth muscle cells.
In the absence of cytokines, elevation of cAMP alone could also increase expression of NOS2 mRNA and protein in smooth muscle cells, although the observations are conflicting, ranging from no or modest effects (35, 36, 40, 72) , to a 13-fold increase in nitrite accumulation when using 8-bromo-cAMP (1 mM) (38) . IL-1␤ by itself caused a modest but significant increase in intracellular cAMP (40) , and the induction of nitrite release due to IL-1␤ was blocked by a selective inhibitor of PKA. This indicates that cAMP may be involved in IL-1␤-dependent signaling pathways leading to NOS2 expression in smooth muscle cells.
Whether pharmacological stimulation of cAMPdependent signaling in smooth muscle cells is therapeutically appropriate is complicated by the dual protective/deleterious effects of NO. For example, the general hypotension occurring in septic shock may be due to vasodilatory actions of NO released by NOS2, and therefore an increase of NOS2 by cAMP would exacerbate the disease. In contrast, in atherosclerosis and balloon-induced injury, increased production of NO by cAMP could prove beneficial by inhibiting platelet and leukocyte adhesion as well as the proliferation of smooth muscle cells.
Renal mesangial cells
The state of contraction of mesangial cells is a finely regulated parameter that determines the glomerular filtration rate. In normal conditions, contraction is induced by hormones like angiotensin II and relaxation is caused by NO released from endothelial cells. In cultured mesangial cells, incubation with cAMP analogs, forskolin, or cholera toxin resulted in significant NOS2 expression when administered alone and dramatically potentiated the induction of NOS2 protein and mRNA by IL-1␤ or TNF-␣ (45). As in arterial smooth muscle cells, the effect of cAMP analogs was dose dependent, and stimulation of NOS2 expression was maximal at high concentrations of the nonmetabolizable dbcAMP (45) . In contrast, exposure to PGE 2 , which elicits a lower increase of cAMP than forskolin or dbAMP, or to concentrations of dbcAMP less than 50 M did not induce expression of NOS2 (47) . This suggests that the potentiation of NOS2 by cAMP in mesangial cells may be a pharmacological but not physiological phenomenon. Nonetheless, pharmacological increase of cAMP may be of therapeutic value in certain forms of glomerulonephritis where induction of NOS2 in mesangial cells may lead to excessive release of NO and vasodilation, thereby exacerbating the disease (73) .
Cardiac myocytes
It has been proposed that NOS2 expression in cardiac myocytes may contribute to inflammatory damage during sepsis, after transplantation, and after ischemia-reperfusion and cause myocardial depression (74) . In cultured cells, the NOS2 expression induced by IL-1␤ and TNF-␣ was enhanced severalfold by forskolin, dbcAMP, and isoproterenol (42, 48 -50) , when assessed at both the nitrite and mRNA levels. In these reports, little or no NOS2 expression was detected in the absence of cytokines, although cAMP alone induced NOS2 expression in neonatal cardiac myocytes when measured by NO production and electron microscopy (75).
Astrocytes and microglia
Astrocytes can express the NOS2 protein in demyelinating diseases (76 -78) , cerebral ischemia (79), viral infection (80) , and Alzheimer's disease (81) . Likewise, NOS2 has been detected in microglia during demyelinating diseases (78) , viral infection (82), and cerebral ischemia (83, 84) , although it is often difficult to ascertain whether the NOS2-expressing cells are infiltrated macrophages instead of resident microglia. Induction of NOS2 in glial cells has been widely accomplished in vitro by exposing cell cultures to agents purported to cause brain diseases, such as cytokines, endotoxins (85) , and the ␤-amyloid protein precursor (86) .
Exposure of rat astrocyte cultures (58) or rat C6 glioma cells (62) to the neurotransmitter noradrenaline significantly decreased LPS-dependent NO release and NOS2 mRNA expression. The inhibition (58) . The effect of noradrenaline could be mimicked by dbcAMP, 8-bromo-cAMP, and forskolin or by direct activation of PKA (59) and could be blocked by inhibition of PKA, but not PKC (62) . Apart from noradrenaline, other natural-occurring cAMP-elevating agents such as endothelin-3 (60), PGE 2 (63) , and dopamine (62) (61) .
The above observations indicate that cAMP-dependent signaling inhibits NOS2 expression in astrocytes. Furthermore, in contrast to studies done in most other cell types, the effect of cAMP on astroglial NOS2 expression has been achieved using endogenous ligands to elevate intracellular cAMP and at concentrations well within the physiological range. Although this suggests that the in vitro findings reveal a response of biological relevance, it has not been studied whether cAMP-elevating neurotransmitters can regulate glial NOS2 expression in vivo. Considering that in some brain areas astrocytes are the main target of noradrenergic neuronal networks, such as the locus ceruleus (87), it is conceivable that expression of glial NOS2 could be suppressed by centrally released noradrenaline.
Because the contribution of NOS2 to brain diseases is controversial, the therapeutic potential of the decrease of NOS2 by cAMP in primary glial cultures is uncertain. This is best illustrated in experimental allergic encephalomyelitis, an animal model for multiple sclerosis, where inhibition of NOS2 expression by different approaches has resulted in both improvement (77) and worsening (88) of the disease. The conflict may arise from the fact that NOS2 is expressed in different glial populations as well as in infiltrated leukocytes during the course of the disease. Hence, depending on its source and timing, NO release may be protective or destructive. Studies in which NOS2 expression is manipulated in a time-and cell-specific manner are necessary to establish the specific role of NO in brain pathologies
Adipose tissue, pancreatic cells, hepatocytes, skeletal muscle, and endothelial cells
Brown adipose tissue (BAT) stands out as an example of a modulatory role of cAMP-dependent signaling on NOS2 expression in vivo under nonpathologic conditions. BAT is involved in thermogenesis in mammals and thus is found in immediate contact with large blood vessels, so that the heat it releases is rapidly transmitted to the blood. The thermogenic activity of BAT is regulated by the sympathetic release of noradrenaline, which in turn is modulated by changes in temperature. Activation of the sympathetic system in rats by exposure to low temperatures resulted in the appearance of NOS2 protein and activity in BAT (56) . These findings were reproduced in cultured adipocytes, mimicking the sympathetic activity with noradrenaline at low concentrations, ␤-adrenergic agonists, and forskolin, all of which induced NOS2 expression in the absence of cytokines or endotoxin (56) . The cAMP-dependent release of NO from adipocytes in vivo could account for the known vasodilation that accompanies noradrenaline-induced thermogenesis and thus facilitate delivery of heat.
Expression of NOS2 in pancreatic cells has been implicated in islet cell death during diabetes, since inhibitors of NOS protect islet cells from IL-1␤-induced damage and loss of insulin release (52) . In these cells (51) as well as in the rat insulinoma ␤-cell line RINm5F (52), exposure to cAMP analogs decreased NOS2 expression, suggesting a protective role for cAMP-dependent regulation of NOS2.
NOS2 expression may also contribute to the damage that occurs in liver hepatocytes during sepsis via inhibition of glycogenolysis and gluconeogenesis. Since glucagon is released during sepsis, the effects of this hormone on NOS2 induction have been characterized. Using primary rat hepatocyte cultures, Harbrecht et al. (54) and Smith et al. (53) demonstrated that the endotoxin or cytokine-mediated induction of NOS2 is decreased by coincubation 1 M glucagon (which activates cAMP signaling), that the inhibition is replicated by dbcAMP or forskolin, and that the effect of glucagon is reversed by incubation with an adenylate cyclase inhibitor. These findings are consistent with a protective role of the glucagon released during sepsis by counteracting the actions of NOS2.
NOS2 appears in skeletal muscle during myositis (89) . In addition, brain endothelial cells express NOS2 protein during embryonic and postnatal development (90), after cerebral ischemia (83) , and in Alzheimer's disease (91) . Evidence for a role of cAMP in regulating NOS2 expression in skeletal muscle or brain endothelium is limited at present to studies in cell lines that show a stimulatory effect of forskolin or dbcAMP (55, 57, 92) .
Studies in human cells
Few studies exist concerning the effect of cAMP on human NOS2 expression. In isolated human myo-cytes, ␤-endorphins, acting via cAMP-dependent pathways, increase expression of NOS2 (34) . In contrast, in the human DLD epithelial cell line, neither forskolin nor 8-dibutyryl-cyclic AMP induced NOS2 mRNA by themselves, nor do they alter NOS2 mRNA induction in response to cytokines (93) .
MOLECULAR MECHANISMS UNDERLYING cAMP EFFECTS
The results described above clearly indicate that cAMP can modulate endotoxin-and cytokine-induced expression of NOS2, although opposite effects have been observed in different cell types, being either stimulatory or inhibitory in macrophages (possibly depending on the extent of inflammatory activation), stimulatory in smooth muscle cells, adipocytes, skeletal muscle, and brain endothelial cells, and primarily inhibitory in pancreatic, liver, and glial cells. Since cAMP potentiates or inhibits the effects of LPS, IL-1␤, TNF-␣, and IFN␣, it is likely that a step common to these various inducers is targeted. In some cases (e.g., in alveolar macrophages in vivo and mesangial cells), cAMP alone is sufficient to stimulate NOS2 expression.
Regulation of NOS2 mRNA steady-state levels and stability
Unlike the two other NOS isoforms, the NOS2 enzyme is constitutively active due to an essentially irreversible binding of calmodulin to the NOS2 protein (94) , which renders NOS2 activity insensitive to changes in calcium concentrations within the physiological range of 100 nM to 1 M. [The calcium independence of NOS2 is not absolute; high concentrations (5 mM) of the calcium chelator EGTA cause up to 30% inhibition of NOS2 isolated from macrophages (95) .] NOS2 activity is therefore dependent primarily on NOS2 protein concentration, as determined by NOS2 mRNA contents, which in turn is dependent on NOS2 gene transcriptional rate and mRNA stability. There is general consensus that the cAMP-induced changes in NOS2 protein are accompanied by equivalent changes in the steady-state levels of NOS2 mRNA, both in the stimulatory and inhibitory modes. Thus, NOS2 mRNA levels are down-regulated by cAMP in astrocytes (59, 62) , Kupffer cells (29) , hepatocytes (54) , and islet cells (51) and up-regulated in macrophages (24, 26, 33, 39) , smooth muscle cells (35) (36) (37) (38) 42) , mesangial cells (45, 46) , myocytes (41, 42) , an astrocyte cell line (61) , adipocytes (56) , and skeletal muscle cells (55) .
Most studies report no effect of cAMP on NOS2 mRNA stability, and nuclear runoff experiments as well as promoter studies have confirmed that cAMP regulates NOS2 gene transcription both when acting in a stimulatory (45, 96) and inhibitory (29, 62) mode. However, it has been reported that elevations of cAMP can stabilize NOS2 mRNA (41, 45) , even in cells where cAMP reduces transcription of the NOS2 gene, and its net effect is inhibitory (62) . Together, this evidence points to transcription as the primary target of cAMP-activated signaling, but opens the possibility of a role for regulation of message stability in NOS2 expression.
Structure of the NOS 2 promoter
Changes in gene transcription are ultimately the result of changes in promoter activation. The NOS2 promoter has been cloned from mouse (97, 98) , human (99 -101) , and rat (102, 103; V. Gavrilyuk and D. L. Feinstein, unpublished results). However, analysis of the effects of cAMP has so far been carried out only with rat and mouse promoters. Since differences in promoter sequence among species suggest different transcriptional regulation, findings obtained with rodent promoters should be extrapolated to other species only with caution.
The NOS2 promoter contains consensus binding sites for numerous transcription factors that could mediate the effect of cAMP (Fig. 1) . For the purposes of this review, we will focus our attention on three transcription factors that have been well characterized: NF-B, CREB, and C/EBP. NF-B is the best-characterized activator of gene expression during inflammatory and immunological events (104) . It consists of dimers of members of the Rel protein family, and in resting conditions is maintained in the cytoplasm due to tight association with inhibitory IB proteins (105) . On exposure to LPS or cytokines, IB is phosphorylated and degraded, thus allowing NF-B to migrate to the nucleus and trigger transcription.
There are two binding sites for NF-B within the rodent NOS2 promoters: a downstream, or proximal, site located 80 to 90 bases upstream from the transcriptional start site, and a second, distal site located roughly 980 bases upstream. DNA footprinting analysis of the mouse macrophage (106) and rat cardiac myocyte (50) NOS2 promoter region has provided direct proof of occupation of NF-B binding sites after LPS stimulation. The relative importance of the two NF-B binding sites for NOS2 induction is controversial. In the initial characterization done in macrophage RAW 264.7 cells (97), removal of the proximal B site abrogated all response to LPS induction, whereas an upstream construct, containing the distal but not the proximal B site did not respond to LPS plus IFN␥. This suggested that in macrophages, the distal B site is not critical for induction by LPS. In contrast, using the same mouse promoter in rat A7r5 vascular smooth muscle cells revealed that deletion of the distal B site by mutagenesis reduced induction by cytokines only ϳ35%; moreover, a 112 bp promoter region containing only the upstream B site could confer NOS2 induction by cytokines (107) . Finally, it has been reported (108) that both proximal and distal B sites were necessary for full induction by a combination of LPS plus IFN␥. Together, these results support the idea that NF-B-dependent pathways involved in NOS2 expression may vary depending on cell type and the particular combinations of cytokines and LPS used. A central role in inflammation for transcription factors other than NF-B is now recognized. This is the case of C/EBP, which consists of a family of leucine zipper transcription factors comprising six members (␣,␤,␥,␦,ε,) ubiquitously expressed in mammalian cells that play pivotal roles in cellular differentiation, energy metabolism, and inflammatory and immunological functions (for a review, see ref 109 ). The C/EBP isoforms interact with each other to produce multiple combinations of dimers, which are capable of regulating transcription by binding to cognate sites in gene promoters. The rat NOS2 promoter contains four putative C/EBP binding sites (Fig. 1 ).
An extensively documented mechanism by which activation of PKA modulates transcription is phosphorylation of the cAMP binding protein CREB. A member of the class of DNA binding proteins with a leucine zipper structure, unphosphorylated CREB is constitutively present in the nucleus. Phosphorylation by PKA catalytic subunit increases its transactivating capacity in two ways. First, it increases the binding affinity of CREB homodimers for the cAMPresponsive element (CRE) sites present in the promoter regions of target genes. Second, it triggers the association of CREB to a CREB binding protein (CBP), a transcriptional coactivator that acts by recruiting and/or stabilizing factors at the transcriptional start site (110) . Although the rat NOS2 promoter contains two CRE sites, the corresponding sites in the mouse promoter do not conform to the consensus CRE motifs, suggesting that binding (or at least canonical binding) of CREB to these sites does not mediate either the inhibitory or potentiating effects of cAMP.
In addition to being a coactivator of CREB, CBP interacts with several other transcription factors including C/EBP, NF-B, c-jun, c-Myb, GATA-1, c-fos, and steroid receptors (111) . The discovery of CBP and its interactions with a wide variety of transcription factors has reinforced the concept that the regulation of gene transcription is dependent on physical interactions between multiple factors within the nucleus.
Increase in NOS2 transcription by cAMP
Since numerous precedents for activation of NF-B by cAMP exist (112) , it has been explored whether NF-B activation is increased in cells in which cAMP potentiates NOS2 expression. However, electrophoretic mobility shift assays (EMSAs) have revealed that neither translocation of NF-B to the nucleus nor binding to B DNA are altered (40, 113, 114) . In mesangial cells, where cAMP alone triggers NOS2 expression to an extent comparable to that elicited by IL-1␤, mutation of the proximal NF-B binding site in the NOS2 promoter had no effect on the induction by cAMP but completely abolished the induction caused by IL-1␤ (96) . Taken together, these findings suggest that cAMP-dependent potentiation of NOS2 transcription is independent of changes in NF-B activation. Nonetheless, it should be stressed that 1) experiments of mobility shift assays have not addressed the potentially different contributions of the distal vs. the proximal NF-B binding sites, and 2) cAMP-dependent phosphorylation of NF-B can increase its transcriptional activity without altering EMSA results (114) .
The absence of any overt effect on NF-B activation has prompted investigations of whether activation of other transcription factors is altered by cAMP. To narrow down the cis-elements involved in the induction of NOS2 expression by dbcAMP, Eberhardt et al. (96) tested in mesangial cells the activity of serial deletion constructs of the NOS2 promoter. Identical levels of induction were achieved using a promoter extending to nucleotide Ϫ1700 as compared to one extending only to Ϫ526, indicating that the majority of important cis-elements for induction by cAMP (as well as by IL-1␤) are located within 526 bp of the transcriptional start site. Focusing on the three C/EBP sites present in this region, they observed that a shorter promoter, lacking the most distal site (CEBP1) had slightly diminished (75%) induction compared to control, whereas further removal of the central C/EBP site (C/EBP2) abolished cAMP induction altogether. Similarly, point mutation of the central C/EBP2 diminished induction to ϳ50% of control values. These data point to a role for C/EBP1 and 2 sites in the induction by cAMP, with C/EBP2 playing a predominant role. Using the central C/EBP2 sequence as a probe, EMSA revealed that cAMP induces binding to this region of a mixture of heterodimers composed of C/EBP-␤, C/EBP-␦, and CREB, a finding also reported previously (50) . No mobility shifts were observed using the most proximal C/EBP site (C/ EBP3), suggesting that this site does mediate the cAMP effects.
It thus appears that in mesangial cells, stimulation of the cAMP-PKA signaling pathways activate C/EBP members as well as CREB, both of which could enhance NOS2 transcription by binding to C/EBP sites, thus potentiating the activity of the CCAAT box. The homology between CRE and C/EBP sites may allow for the binding of CREB to the latter sites; not surprisingly, C/EBP proteins have also been shown to recognize the CRE motif (115) . It remains to be determined, however, whether activation of the CCAAT box also underlies the actions of increased cAMP in cells like macrophages or aortic smooth muscle cells, in which cAMP potentiates the effect of cytokines but has no or low stimulatory capacity on its own. An equally intriguing question is whether the CREB-mediated activation of the CCAAT box is absent in cells where cAMP is inhibitory.
Decrease in NOS2 transcription by cAMP
Analogous to the experiments described above, precedents exist for inhibition of NF-B activation by elevated cAMP (116) . Therefore, the effects of cAMP on NF-B activation have been examined in cells where cAMP decreases NOS2 induction. In Kupffer cells (29) , forskolin abolished two hallmarks of the activation of NF-B by LPS, namely, the degradation of IB␣ and the translocation of the NF-B subunit p65 to the nucleus. In addition, forskolin up-regulated the expression of IB␣ mRNA, which possibly led to increased cytoplasmic IB␣ and counteracted the LPS-induced degradation. These findings suggest that the inhibitory effect of cAMP in macrophages is due to increased stabilization of NF-B in the cytoplasm by IB␣. Conceivably, PKA activation may inhibit the IB kinase activities involved in phosphorylation of IB␣ prior to its degradation, although the characterization of such reactions has not been addressed.
Decreased NF-B activation associated with inhibition of NOS2 expression has also been described in primary astrocyte cultures (59) . In a second study also using primary astrocytes, however, no changes in either NF-B nuclear uptake, DNA binding, or subunit composition were observed up to 7 h after incubation with noradrenaline to elevate cAMP levels (62) . A conciliatory explanation is that the different levels of cAMP achieved by noradrenaline vs. forskolin or the different NF-B-activating agents used may account for the conflicting results. Furthermore, the decrease in NF-B nuclear migration reported was slight and difficult to reconcile with the up to 80% decrease of NOS2 transcription induced by cAMP (59) . This suggests that unlike the studies of Kupffer cells described above, mechanisms other than regulation of nuclear uptake of NF-B account for the inhibitory effect of cAMP in astrocytes. The absence of cAMP effect on NF-B activation has been also reported in endothelial cells (117) , again suggesting that effects on other transcription factors may mediate cAMP inhibitory actions. However, as is the case for stimulatory actions of cAMP, the possibility of a PKA-dependent inhibitory phosphorylation of NF-B cannot be ruled out.
Recently, a hypothesis has been offered to explain how cAMP inhibits transcription of adhesion molecules in endothelial cells that could be applicable to the inhibitory actions of cAMP on NOS2 expression, involving regulation of the transcriptional coactivator CBP. Overexpression of CBP enhances p65-mediated transcription via binding of CBP to the carboxyl-terminal region of p65 (118, 119) , thus indicating that CBP is a transcriptional coactivator of p65. Since CBP can also bind to phosphorylated CREB, CREB and p65 may compete for the binding of CBP. Thus, increased amounts of activated CREB may recruit the available CBP, thereby diminishing the CBP available for activation of p65. In support of this idea, it has been shown in endothelial cells that the inhibitory effects of cAMP were reversed by overexpression of CBP (119) . Similar studies have not yet been undertaken in the context of NOS2 expression.
To better characterize the areas of the NOS2 promoter sensitive to the inhibitory actions of cAMP, a functional analysis of the promoter has been carried out using C6 glioma cells as a model for astrocytes (62) . In C6 cells stably transfected with the mouse NOS2 promoter attached to the bacterial CAT gene, noradrenaline reduced the LPS plus cytokine-induced reporter gene expression. In contrast, this suppression was lost when a truncated promoter was used (which extended only to the proximal NF-B binding site). These results confirm that cAMP-dependent inhibition occurs at the level of NOS2 transcription and point to an area of the NOS2 promoter located upstream of the proximal NF-B site as the target of cAMP.
A surprising outcome of the above described studies was that incubation with noradrenaline potentiated nearly threefold the cytokine-dependent induction of NOS2 expression in cells transfected with the truncated promoter. Moreover, noradrenaline alone dramatically induced the activity of this minimal promoter, thus conferring unto these cells a phenotype more similar to that of mesangial cells, which respond to cAMP alone. These results demonstrate that in astrocytes, cAMP-dependent signaling can be both stimulatory and inhibitory of NOS2 expression and that under normal conditions (i.e., in the context of the endogenous gene or of the whole promoter), the inhibitory action prevails. These results are consistent with a model in which a cAMPactivated suppressive factor binds to an upstream location in the NOS2 promoter, a cAMP-activated potentiating factor binds to a downstream area, and, in the presence of both factors, inhibition is observed. Further analysis of these cell lines, which can be manipulated to permit either suppression or potentiation of NOS2 expression, should help clarify the mechanisms and factors mediating the dual actions of cAMP.
CONCLUDING REMARKS
Stimulation of cAMP-mediated signaling inhibits or stimulates expression of NOS2 in many cells. Even though this conclusion is supported by a wealth of biochemical and pharmacological evidence, an understanding of the molecular mechanisms responsible is still limited. Regulation of NOS2 gene transcription appears to be the primary mechanism of action of cAMP; whether it is stimulatory or inhibitory hinges on the cell-specific regulation of transcription factors including CREB, NF-B, and C/EBP. However, it may be premature to pronounce cAMP a widespread regulator of NOS2 expression, as most studies have been performed using cells or cell lines derived from the rat. It is also important to remember that the majority of existing evidence derives from cultured cells and that in many experiments, elevation of intracellular cAMP levels was achieved using stable, membrane-permeable cAMP analogs such as dbcAMP. The concentrations tested of these analogs far exceed any increase in intracellular cAMP due to physiological messengers such as neurotransmitters, the effects of which have been examined in only a few instances. Therefore, it is not yet clear that the actions of cAMP in vitro extend to in vivo. It remains to be explored at large whether central or peripheral neuronal networks, or cAMPelevating agents present in blood, are able to regulate NOS2 expression. Whether or not its effects are physiological, increases of cAMP can be induced with therapeutic goals in mind; however, this approach should be carefully examined in each case, since NO can be cytotoxic or protective, depending on the context of its release.
